Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

Abstract

Our results clearly show for the first time that the reduction of blood pressure, together with 24 h urinary albumin excretion rate - two established cardiovascular risk factors, obtained during Simvastatin therapy in hypertensive type 2 diabetic patients - is in large part independent from the reduction of LDL Cholesterol.